A Randomized, Open-label, Single Dose, Crossover Phase 1 Study to Compare the Pharmacokinetic Characteristics of GLA5PR GLARS-NF1 Tablet 300 mg and GLA5PR GLARS-NF3 Tablet 300 mg in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Pregabalin (Primary)
- Indications Pain
- Focus Pharmacokinetics
- Sponsors GL PharmTech
- 11 Apr 2017 Status changed from active, no longer recruiting to completed.
- 18 Nov 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 07 Nov 2016 New trial record